The influence of obstructive sleep apnea and continuous positive airway pressure on the nasal microbiome

C. LENK1, M.E. MESSBACHER1, J. ABEL1, S.K. MUELLER1, K. MANTSPOULOS1, A.O. GOSTIAN1, M. SIEVERT1, S. WIRTZ2, F. MARXREITER3, J. WINKLER3, H. IRO1, M. TRAXDORF1

1Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Waldstraße, Erlangen, Germany
2Department of Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße, Erlangen, Germany
3Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage, Erlangen, Germany

Abstract. – OBJECTIVE: The aim of this study was to investigate the influence of obstructive sleep apnea and continuous positive airway pressure on the nasal microbiome.

PATIENTS AND METHODS: Endonasal swabs from the olfactory groove of 22 patients with moderate and severe obstructive sleep apnea (OSA) and a control group of 17 healthy controls were obtained at the Department of Otorhinolaryngology of the Friedrich-Alexander-Universität Erlangen-Nürnberg. 16S rRNA gene sequencing was performed to further evaluate the endonasal microbiome. In a second step, the longitudinal influence of continuous positive airway pressure (CPAP) therapy on the nasal microbiome was investigated (3-6 and 6-9 months).

RESULTS: Analysis of the bacterial load and β-diversity showed no significant differences between the groups, although patients with severe OSA showed increased α-diversity compared to the control group, while those with moderate OSA showed decreased α-diversity. The evaluation of longitudinal changes in the nasal microbiota during CPAP treatment showed no significant difference in α- or β-diversity. However, the number of bacteria for which a significant difference between moderate and severe OSA was found in the linear discriminant analysis decreased during CPAP treatment.

CONCLUSIONS: Long-term CPAP treatment showed an alignment of the composition of the nasal microbiome in patients with moderate and severe OSA as well as an alignment of biodiversity with that of the healthy control group. This change in the composition of the microbiome could be both part of the therapeutic effect in CPAP therapy and a promoting factor of the adverse side effects of the therapy. Further studies are needed to investigate whether the endonasal microbiome is related to CPAP compliance and whether CPAP compliance can be positively influenced in the future by therapeutic modification of the microbiome.

Key Words: Nasal microbiome, Microbiome, Obstructive sleep apnea, CPAP, 16S rRNA.

Introduction

Obstructive sleep apnea is a multifactorial disease with multiple genes, environmental influences and development factors that are closely related to this potentially hazardous disease. According to a 1993 study, 2-4% of the middle-aged population were affected by obstructive sleep apnea. However, recent epidemiological studies show that the prevalence has increased by 14-55% in the last 20 years, and today 13% of the male and 6% of the female population in the USA suffer from obstructive sleep apnea. The prevalence in patients with cardiovascular diseases is about 2 to 3 times higher. Furthermore, the prevalence of obstructive sleep apnea (OSA) in the general population is unfortunately largely underestimated, with about 82% of men and 93% of women remaining undiagnosed. The most common therapy for all degrees of obstructive sleep apnea is nocturnal positive airway pressure (PAP) in the form of continuous PAP mode (CPAP, continuous PAP). However, a continuous positive pressure of dry or humidified air in the upper airways is associated with mucosal problems and subsequent airway inflammation. Therefore, subjective and objective reductions in nasal patency, rhinitis,
sinonasal side effects and associated CPAP mask leakage are common\textsuperscript{9}. The nasal cavity as the first part of the respiratory system is responsible for processing and filtering the outside air enriched with organic and inorganic particles\textsuperscript{10}. In this regard, the upper respiratory tract is an active part of the immune system and is colonized by various microbes. The sinonasal microbiome is a complex symbiotic organization of bacteria, fungi and the nasal microenvironment. The alteration of microbiomes due to extrinsic and intrinsic factors has been widely discussed in recent literature. Our knowledge of this complex human-microbiological interaction has increased greatly in recent years. Current investigations\textsuperscript{11,12} on the nasal and gut microbiome have shown that the microbial milieu is responsible for a healthy state of the mucosa, while dysbiosis can lead to irritation, inflammation and allergies. It thus seems logical that the microbiome plays a significant role in the course of host metabolic and immunological processes\textsuperscript{13,14}. A healthy microbiome is important for protecting epithelial integrity, leads to the production of immunoglobulin, induces regulatory T-cells\textsuperscript{15} and stimulates the formation of the mucus blanket and nutrient metabolism\textsuperscript{16}. It has a significant effect on general inflammatory and allergic disorders\textsuperscript{17-21}. A few patterns such as Staphylococcus epidermidis, Staphylococcus aureus and Corynebacterium have been identified\textsuperscript{22-24} and seem to be present in a healthy nasal microbiome. Microbial compositions of the middle meatus and the sphenoethmoidal recess seem to be identical, while the composition of the anterior nose is different, with a greater proportion of Actinobacteria and Firmicutes\textsuperscript{25}. The association of recurrent obstruction in OSA and consecutive airway inflammation with local subepithelial oedema and hypoxia, as well as systemic inflammation, is already well known\textsuperscript{10,13,14}. The altered microenvironment can lead to dysbiotic colonization of the airways and even increase the inflammatory process\textsuperscript{10,14}. Various clinical studies\textsuperscript{26,27} have used scores to show that patients with OSA report significantly more rhinological symptoms. This correlation between clinical symptoms and the severity of OSA may be caused by an altered nasal microbiome. The latest study on the nasal microbiome by Wu et al\textsuperscript{10}, presented a nasal microbiome enriched with several oral commensals, inflammatory signatures and an increased Shannon diversity index (SDI) in subjects with severe OSA. In a control after only three months of CPAP treatment, no significant alterations in the composition or diversity of the nasal microbiome were observed\textsuperscript{10}. Due to the significant influence of the environment and other factors on the microbiome, the aim of our study was to investigate the possible association between obstructive sleep apnea and nasal microbiome and long-term changes in the nasal microbiome caused by long-term CPAP usage in a middle-aged European patient population.

**Patients and Methods**

**Study design and Participants**

This single-center prospective controlled study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Ethics Committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg (Ref-No. 284_16 B). Inclusion criteria comprised men and women with untreated obstructive sleep apnea (n=22) and healthy controls with an unremarkable sleep history and without symptoms of acute or chronic rhinosinusitis (n=17). Exclusion criteria comprised patients with central or mixed apnea, patients under the age of 21 or over 90, patients with any acute or chronic condition that would limit the ability to participate in the study, patients with any treatment or surgery of the upper airway system due to OSA, patients with psychological impairment and pregnant woman. Informed consent was obtained from all individual participants included in the study. This diagnostic study was reported according to the STARD requirements.

All patients with OSA were first diagnosed and treated at the Department of Otorhinolaryngology Head and Neck Surgery of the Friedrich-Alexander-Universität Erlangen-Nürnberg without prior CPAP therapy. OSA was defined using diagnostic criteria of the International Classification of Sleep Disorders (ICSD-3): mild OSA apnea-hypopnea index (AHI) ≥ 5/h (5 apnea and hypopnea events per hour with sleep-related symptoms and comorbidities), moderate OSA (AHI from 15/h to 29/h), severe OSA (AHI ≥ 30/h)\textsuperscript{28,29}.

Polysonomography (PSG) was carried out using the 33-channel cardiorespiratory SOMNO screen diagnostic system (SOMNOmedics, Randersacker, Germany). The technical implementation of the PSG followed the recommendations of the American Academy of Sleep Medicine (AASM)\textsuperscript{30}. The sleep stages and associated events were analyzed and scored visually according to the AASM criteria (version 2.4, 2017)\textsuperscript{31}. In
the night following PSG, CPAP titration was performed according to the clinical guidelines of the Positive Airway Pressure Titration Task Force of the AASM.

Sample Collection
All samples were collected at the Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg. SalivaGene Buccal Swabs (Stratec molecular, Birkenfeld, Germany) with DNA stabilizer for DNA extraction (Stratec molecular, Birkenfeld, Germany) were taken noninvasively from the deep mucosa of the olfactory groove on the right or left side and frozen at -80°C until DNA extraction.

Concerning the OSA group, follow-up samples were collected after 3-6 and 6-9 months of CPAP therapy. Patients with low CPAP compliance (less than 6 h CPAP therapy per night) were excluded.

DNA Extraction
QIAamp UCP DNA Micro Kit plus Pathogen Lysis Tube S (Qiagen GmbH, Hilden, Germany) were used to extract the total genomic bacterial DNA from the DNA stabilizer and swab heads following the manufacturer’s instructions. After DNA extraction all samples underwent a DNA concentration measurement by NanoDrop 200 (Thermo Fisher Scientific, Wilmington, USA) and were stored at -80°C until PCR processing.

Quantitative PCR
To amplify the V3+4 region of bacterial 16S rRNA gene region-specific primers containing dual barcodes and Illumina flow cell adaptor sequences and NEBNext Q5 Hot Start Hifi PCR Kit (New England Biolabs, Ipswich, MA, USA) were employed. For each sample, 10 ng of metagenomic template DNA were used in a reaction consisting of 35 PCR cycles (98°C 15 seconds, 58°C 20 seconds, 72°C 40 seconds). The amplicons were purified with Agencout AMPure XP Beads (Beckmann Coulter, Krefeld, Germany), quantified using a Qbit device (Thermo Fisher, Waltham, MA, USA), normalized, and pooled before sequencing on an Illumina MiSeq device using a 600-cycle paired-end modus. Subsequently, the read FASTQ files were bioinformatically processed (merging, demultiplexing, quality filtering, dereplication, chimera removal) using Usearch 11 according to the Uparse pipeline. Operational taxonomic units (OTUs) were picked at a threshold of 97% similarity and taxonomically classified by comparing the representative OTU sequence to the reference file of the ribosomal database project (RDP version 16, available at: http://rdp.cme.msu.edu).

Statistical Analysis
All data were processed via Microbiomeanalyst (available at: https://www.microbiomeanalyst.ca). Paired nonparametric statistics (Mann-Whitney U Test) were used for comparing the alpha diversity between baseline samples and longitudinal samples (pretherapeutic and post 3-6 and 6-9 months). To evaluate differences in β-diversity between the groups, we used permutational multivariate ANOVA (PERMANOVA) and PAST 4.0. To evaluate the taxonomical differences between the groups, we used linear discriminant analysis (LAD) including effect size (LEfSe) and the Mann-Whitney U test for two categories. In the case of longitudinal taxonomical differences, the Wilcoxon rank sum test and LEfSe were used. For demographic data the Kruskal-Wallis’ test was used for differences in 3 groups and the Mann-Whitney U test for follow-up analysis. For small numbers Fisher’s Z was used instead of Chi-square tests. A $p$-value <0.05 was considered as statistically significant across all tests.

Results

Study Cohorts
A total of 39 subjects were enrolled in the study: 17 subjects in the control group and 22 subjects in the OSA group. The OSA group could be further divided into the two subgroups moderate ($n=9$) and severe OSA ($n=13$) (Table I).

Microbial Signatures of the Study Cohorts
Concerning the overall bacterial load (absolute abundance) from the analyzed cohorts, no significant differences could be detected between the control group and the OSA group or OSA subgroups, respectively ($p=0.217$) (Figure 1, Supplementary Table I).

Analysis of the microbial diversity ($\alpha$-diversity) of the control group and the OSA group showed no significant differences in terms of the Shannon diversity index (SDI), markers of richness (biodiversity, total number) or the abundance (distribution) of the taxa of a given sample (Mann-Whitney U test; $p>0.999$). Concerning the analysis of the subgroups, patients suffering from severe OSA had an increased SDI compa-
red to the control group (Mann-Whitney U test; $p=0.202$), while patients suffering from moderate OSA showed a decreased SDI (Mann-Whitney U test; $p=0.100$). The difference between patients with moderate or severe OSA was significant (Mann-Whitney U test; $p=0.035$) (Figure 2, Supplementary Table II).

Analysis of β-diversity based on Bray-Curtis using PAST 4.0 as a measure of differences between the taxonomical microbial abundances from different samples showed no differences between the control group and OSA group (PERMANOVA; $F = 0.329$, $p = 0.9637$). Comparison of β-diversity between the control group and moderate (PERMANOVA; $p=0.871$) or severe OSA group (PERMANOVA; $p=0.585$) as well as comparison of the moderate and severe OSA groups showed no differences (PERMANOVA; $p=0.574$).

**Taxonomical Differences**

The most abundant taxa across all groups were *Corynebacteriaceae*, *Carnobacteriaceae* and *Staphylococcaceae* (Figure 3, Supplementary Table III).

To evaluate detailed taxonomical differences between the control group and the OSA group

<table>
<thead>
<tr>
<th></th>
<th>CG (N = 17)</th>
<th>Moderate OSA (N = 9)</th>
<th>Severe OSA (N = 13)</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (♂)</td>
<td>8 (47.1 %)</td>
<td>8 (88.9 %)</td>
<td>10 (76.9 %)</td>
<td>$p = 0.062$, $V = 0.377$</td>
</tr>
<tr>
<td>Age</td>
<td>58.00 [49.50; 62.50]</td>
<td>50.00 [43.00; 55.50]</td>
<td>53.00 [47.00; 63.50]</td>
<td>$H_{\text{CG}} = 3.12$, $p = 0.209$</td>
</tr>
<tr>
<td>BMI (25.71 [24.03; 30.74])</td>
<td>29.76 [25.56; 31.39]</td>
<td>32.05 [29.23; 39.97]</td>
<td>$H_{\text{OSA}} = 11.05$, $p = 0.004$</td>
<td></td>
</tr>
<tr>
<td>Post-hoc</td>
<td>$p = 0.269$, $r = 0.217$</td>
<td>$p = 0.001$, $r = 0.584$</td>
<td>$p &lt; 0.001$, $r = 0.834$</td>
<td></td>
</tr>
<tr>
<td>Baseline AHI</td>
<td>23.9 [20.45; 27.90]</td>
<td>61.70 [43.60; 85.20]</td>
<td>$p = 0.229$, $r = 0.256$</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>15 (88.2 %)</td>
<td>4 (44.4 %)</td>
<td>8 (69.2 %)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>0 (0.0 %)</td>
<td>3 (33.3 %)</td>
<td>2 (15.4 %)</td>
<td></td>
</tr>
<tr>
<td>No but previously</td>
<td>2 (11.8 %)</td>
<td>2 (22.2 %)</td>
<td>2 (15.4 %)</td>
<td></td>
</tr>
</tbody>
</table>

Table I. Baseline characteristics. Obstructive sleep apnea: OSA, Control Group: CG; Body mass: BMI; apnea-hypopnea index: AHI, continuous positive airway pressure: CPAP.

Figure 1. Bacterial load or absolute abundance (16S rRNA gene copies/μl) of the control group and OSA subgroups. Obstructive sleep apnea: OSA, Control Group: CG. Moderate and severe OSA group has a few outliers plotted as small circles for outliers which are more than 1.5 times but less than 3 times the interquartile range above the third quartile or below the first quartile and * for outliers which are more than 3 times the interquartile range above the third quartile or below the first quartile.
linear discriminant analysis (LDA) was used taking the effect size (LEfSE) into consideration. The nasal microbiota of the OSA group compared to the control group was significantly enriched with *Xanthobacteraceae* (Wilcoxon test; *p*=0.011), while the abundance of *Brucellaceae* (Wilcoxon test; *p*=0.006), *Burkholderiales incertae sedis* (Wilcoxon test; *p*=0.002), *Erysipelothrichaceae* (Wilcoxon test; *p*=0.021) were significantly decreased. The nasal microbiome of patients with moderate OSA was enriched with *Xanthobacteraceae* (Wilcoxon test; *p*=0.006), while the abundance of *Comamonadaceae* (Wilcoxon test; *p*=0.014), *Burkholderiales incertae sedis* (Wilcoxon test; *p*=0.047), *Brucellaceae* (Wilcoxon test; *p*=0.037) and *Lachnospiraceae* (Wilcoxon test; *p*=0.035) was decreased compared to the nasal microbiota of the control.

**Figure 2.** α-diversity of the control group, OSA group and OSA subgroups. **A**, Shannon diversity index (SDI) of the control group and the OSA group. **B**, SDI of the control group and OSA subgroups. Obstructive sleep apnea: OSA; Shannon diversity index: SDI. Severe OSA group has two outliers plotted as small circle for the outlier which is more than 1.5 times but less than 3 times the interquartile range below the first quartile and * for the outlier which is more than 3 times the interquartile range below the first quartile.
group in subjects with severe OSA. The amount of Actinomycetaceae (Wilcoxon test; \(p=0.048\)), Peptoniphilaceae (Wilcoxon test; \(p=0.016\)) and Xanthobacteraceae (Wilcoxon test; \(p=0.033\)) was increased, while Brucellaceae (Wilcoxon test; \(p=0.017\)), Burkholderiales incertae sedis (Wilcoxon test; \(p=0.007\)), Desulobacteraceae (Wilcoxon test; \(p=0.044\)), Rhizobiales incertae sedis (Wilcoxon test; \(p=0.044\)), Sinobacteracteraceae (Wilcoxon test; \(p=0.037\)) and Erysipelotrichaceae (Wilcoxon test; \(p=0.026\)) were decreased compared to the control group. Moderate OSA subjects compared to severe OSA subjects showed a higher amount of Actinomycetaceae (Wilcoxon test; \(p=0.042\)), while the amount of Propionibacteriaceae (Wilcoxon test; \(p=0.017\)) and Clostridiales incertae sedis (Wilcoxon test; \(p=0.035\)) was reduced compared to severe OSA subjects. (Figure 4, Supplementary Table IV).

**Effect of CPAP-Treatment on Nasal Microbiome**

To investigate the effect of CPAP treatment on the nasal microbiome of OSA patients, nasal swabs were repeated 3-6 months and 6-9 months after baseline measurement in untreated OSA. Evaluation of the longitudinal change in nasal microbiota showed no difference in SDI (Friedman-ANOVA: \(\chi^2(2)=4.308, p=0.116\)) (Figure 5A, Supplementary Table II).

Differentiated by OSA severity, samples from patients with moderate OSA showed a statistically significant increase in α-diversity after 3-6 months of treatment (Mann-Whitney U test; \(p=0.028, r=0.635\)), while no further change was detected after 6-9 months (Mann-Whitney U test; \(p=0.753, r=0.091\), Friedman ANOVA: \(\chi^2(1)=9.00, p=0.011\)). For the group of patients suffering from severe OSA, no statistically significant difference in α-diversity could be shown after 3-6 and 6-9 months of CPAP treatment (Mann-Whitney U test; \(p=\text{non-significance}\); Friedman-ANOVA: \(\chi^2(1)=0.286, p=0.867\)) (Figure 5B, Supplementary Table II).

Samples from patients with moderate OSA showed no significant differences in β-diversity after 3-6 months of treatment (PERMANOVA; \(F=0.518, p=0.902\)) and no further change after 6-9 months (PERMANOVA; \(F=0.453, p=0.908\)). In summary, longitudinal analysis of β-diversity showed no differences in the moderate OSA group during CPAP treatment (PERMANOVA; \(F=0.526, p=0.971\)).

In the severe OSA group, no differences in β-diversity were detected either (PERMANOVA; \(F=0.937, p=0.540\)). Both follow-up samples showed no statistically significant difference in β-diversity after 3-6 (PERMANOVA \(F=0.658, p=0.817\)) and no changes after 6-9 months of CPAP-treatment (PERMANOVA; \(F=0.801, p=0.662\)). Furthermore, longitudinal taxonomical differences before and under CPAP treat-
The nasal microbiome of subjects with moderate OSA after 3-6 months of CPAP treatment was enriched with **Propionibacteriaceae**, **Alcaligenaceae**, **Clostridiales** and **Streptococcaceae**, while the amount of **Staphylococcaceae**, **Enterobacteriaceae** and **Carnobacteriaceae** was decreased. After 6-9 months the amount of **Staphylococcaceae** decreased further, while **Alcaligenaceae** and **Micrococcaceae** increased (Figure 6A, Supplementary Table III).

In the severe OSA group the microbiome was enriched with **Streptococcaceae** and **Staphylococcaceae** after 3-6 months of CPAP treatment, while after 6-9 months the nasal microbiome showed a decreased amount of **Streptococcaceae**, **Clostridiales** and **Peptoniphilaceae** and an increased amount of **Staphylococcaceae** (Figure 6B, Supplementary Table III).

In addition, a linear discriminant analysis (LDA) was performed to investigate taxo-

---

**Figure 4.** LDA Scores of the OSA group and partitioning into subgroups compared to the control group. **A**, Control group vs. OSA, **B** Control group vs. moderate OSA, **C** Control group vs. severe OSA. Linear discriminant analysis: LDA; Obstructive sleep apnea: OSA; Control Group: CG.
nomical differences in the context of CPAP treatment. A higher absolute LDA score indicates a greater difference in the relative abundance of bacteria. With regard to moderate OSA, 3-6 months of CPAP-treatment resulted in an increase in *Moraxellaceae* (Wilcoxon test; \( p=0.019 \)), *Ruminococcaceae* (Wilcoxon test; \( p=0.015 \)), *Brevibacteriaceae* (Wilcoxon test; \( p=0.028 \)) and *Oxalobacteriaceae* (Wilcoxon test; \( p=0.034 \)), while *Lavobacteriaceae* (Wilcoxon test; \( p=0.020 \)) decreased (Figure 7A, Supplementary Table V). After 6-9 months of CPAP therapy *Ruminococcaceae* (Wilcoxon test; \( p=0.004 \)), *Bacteroidaceae* (Wilcoxon test; \( p=0.012 \)), *Acidaminococcaceae* (Wilcoxon test; \( p=0.036 \)), *Peptostreptococcaceae* (Wil-
Nasal microbiome in OSA and CPAP-treatment

![Figure 6. Taxonomical differences at baseline and after 3-6 and 6-9 months of CPAP-treatment. Longitudinal change in relative abundances in patients with moderate (A) and severe OSA (B).](image)

coxon test; \(p=0.036\), Bacillaceae (Wilcoxon test; \(p=0.043\)), Eubacteriaceae (Wilcoxon test; \(p=0.036\)), Sutterellaceae (Wilcoxon test; \(p=0.005\)), Helicobacteriaceae (Wilcoxon test; \(p=0.043\)) and Desulobacteraceae (Wilcoxon test; \(p=0.030\)) were decreased (Figure 7B, Supplementary Table V). With regard to severe OSA, 3-6 months of CPAP-treatment resulted in a higher amount of Methylobacteriaceae (Wilcoxon test; \(p=0.046\)), Rhodobacteriaceae (Wilcoxon test; \(p=0.039\)), Pseudomonadaceae (Wilcoxon test; \(p=0.013\)), Nocardoidiaceae (Wilcoxon test; \(p=0.027\)), Planctomycetaceae (Wilcoxon test; \(p=0.036\)), Gaiellaceae (Wilcoxon test; \(p=0.021\)) and Mycobacteriaceae (Wilcoxon test; \(p=0.036\)) (Figure 7C, Supplementary Table V). After 6-9 months of CPAP treatment Burkholderiales incertae sedis (Wilcoxon test; \(p=0.018\)) was increased, while Geodermatophilaceae (Wilcoxon test; \(p=0.024\)), Rikenellaceae (Wilcoxon test; \(p=0.010\)), Oxalobacteriaceae (Wilcoxon test; \(p=0.024\)), Actinomycetaceae (Wilcoxon test; \(p=0.031\)), Solirubrobacteraceae (Wilcoxon test; \(p=0.024\)), Acetobacteriaceae (Wilcoxon test; \(p=0.024\)), Enterobacteriaceae (Wilcoxon test; \(p=0.023\)) and Lachnospiraceae (Wilcoxon test; \(p=0.049\)) were decreased (Figure 7D, Supplementary Table V). Compared to each other, severe OSA samples showed a higher amount of Gaiellaceae (Wilcoxon test; \(p=0.024\)), while moderate OSA samples showed a higher amount of Burkholderiales incertae sedis (Wilcoxon test; \(p=0.034\)), Porphyromonadaceae (Wilcoxon test; \(p=0.038\)) and Ruminococcaceae (Wilcoxon test; \(p=0.017\)) after 3-6 months of CPAP treatment. After 6-9 months of CPAP treatment, severe OSA samples showed a slightly higher amount of Burkholderiales incertae sedis (Wilcoxon test; \(p=0.03\)) compared to the moderate OSA group.

Discussion

The results of this study are in line with previous studies\(^{10}\) demonstrating the association of nasal microbiome and OSA. Subjects with severe OSA showed a higher Shannon diversity-index although the results were not significant. According to prior studies\(^{10}\), a correlation between biodiversity and the severity of OSA could not be demonstrated in our study. In contrast, however, a significantly lower diversity in the oropharyngeal microbiome has already been described\(^{35}\) in patients with moderate OSA.

In our study the abundance of Xanthobacteraceae was increased in moderate OSA compared to subjects with no OSA, while the abundances of Burkholderiales incertae sedis, Lachnospira-
ceae, Comamonadaceae and Brucellaceae were decreased. The enrichment of Xanthobacteraceae could also be seen in patients with severe OSA besides an additional enrichment of Actinomycetaeae and Peptophilaceae. While Xanthobacteraceae are well known as transient commensals in the gastrointestinal microbiome, Burkholde- riales incertae sedis and Comamonadaceae have been frequently identified as commensals of the nasal cavity. According to recent studies, Erysipelothrichaceae in gut microbiome is highly coated with IgA, correlates with tumor necrosis factor alpha and seems to affect host cholesterol metabolites. However, the most abundant taxa in all groups were Corynebacteriaceae, Staphylococaceae and Carnobacteriaceae. In addition, Propionibacteriaceae and Micrococcaceae were strongly represented in the control group. Similar to the healthy control group in this study, Propionibacteriaceae, Corynebacteriaceae and Staphylococaceae were frequently identified as predominant patterns of a healthy nasal microbiome in various studies. In summary, the recognition of fundamental links between OSA and the nasal microbiome is complicated by the fact that the microbiome depends highly on the exact anatomical sampling site, such as the anterior nares with a keratinized epithelium or paranasal sinuses with a respiratory epithelium and more moisturized air. The enrichment of anaerobic taxa such as Peptophilaceae may be due to the reduced oxygen content of the airway in OSA or to biofilms leading to a hypoxic environment, as previously described in chronic rhinosinusitis (CRS), whereas more aerobic commensals such as Brucellaceae, Propionibacteriaceae and Burkholderiales are found in a healthy nasal microbiome. The longitudinal study with subjects suffering from moderate OSA who underwent CPAP treatment showed a significant change

Figure 7. Taxonomical differences in the context of CPAP treatment. A positive LDA score is associated with an increase in the relative abundance of bacteria and a negative LDA score is associated with a decrease in the relative abundance of bacteria. A, moderate OSA after 3-6 months of CPAP treatment compared to pretherapeutic samples. B, severe OSA after 3-6 months of CPAP treatment compared to pretherapeutic samples. C, moderate OSA after 6-9 months of CPAP treatment compared to 3-6 months of CPAP treatment. D, severe OSA after 6-9 months of CPAP treatment compared to 3-6 months of CPAP treatment. Linear discriminant analysis: LDA; Obstructive sleep apnea: OSA.
in Shannon diversity towards a higher diversity after 3-6 months of therapy ($p=0.018$), while the number of bacteria for which a significant difference was found between moderate and severe OSA, in the linear discriminant analysis, decreased during CPAP treatment. After 6-9 months of CPAP treatment, the biodiversity seems to become more similar to that of the control group. Compared to the results of Wu et al\textsuperscript{10}, the effect of CPAP treatment on the nasal microbiome seems to need more than 3 months of therapy. In general, higher diversities seem to be a marker for a healthier microbiome; higher diversity in the sinonasal microbiome also seems also to be associated with a better postoperative outcome\textsuperscript{43} and improved health, whereas lower diversity has been observed\textsuperscript{44} in patients with chronic rhinitis. A similar effect could also be observed in studies\textsuperscript{45,46} on the gut microbiome. In the severe OSA group, higher numbers of Rhodobacteriaceae and Burkholderiales were detected, whereas Enterobacteriaceae decreased under therapy. As mentioned, Burkholderiales are already a known component of the nasal microbiome, and both are considered aerobic bacteria. A possible explanation for the higher concentration of aerobic bacteria on CPAP therapy could be that, on CPAP treatment, obstruction is prevented and better oxygenation of the mucus in the airways is ensured. Thus, several studies\textsuperscript{47} have already shown that different oxygen concentrations are an important parameter affecting the microbiota. In subjects suffering from severe OSA, the relative abundance of Staphylococcaceae increased under CPAP therapy. Although not significant in the linear discriminant analysis, the increased amount of Staphylococcaceae could be caused by several factors already discussed in the literature: higher CPAP pressure and an irritation of the epithelium due to a contamination of the CPAP device with Staphylococcaceae during longer treatment or caused by changing environmental conditions such as winter and summer, colder or warmer temperatures\textsuperscript{48,49}. In terms of future therapeutic implications, altering and optimizing the microbiome is an important therapeutic target. For example, in mouse models, fecal microbiota transplants, which are already established in gastroenterology, have been shown to help stabilize a healthy gut microbiome and reduce dysbiosis, and are considered a potential factor in the field of psychiatric or neurological disorders. Similarly, it is conceivable that in OSA patients, therapeutic modification of the sinonasal microbiome via the probiotics in a nasal spray might reduce the symptoms of rhinitis and sinusitis during CPAP treatment and thus improve compliance\textsuperscript{50-52}. The intestinal microbiome is also becoming increasingly important in oncological issues, and the microbial composition seems to be related to both the development of cancer and the specific treatment in terms of immunotherapy efficacy\textsuperscript{53}.

**Limitations**

However, some limitations of the study must also be considered. Due to numerous general factors influencing the diversity of the microbiome (gender, age, geographical location, climate, culture, lifestyle habits, nicotine and alcohol consumption, diet, obesity, etc.), the interpretation of individual study results in the context of existing scientific knowledge is considerably complicated or even limited\textsuperscript{44}. In addition, viral and fungal populations could also have an impact on the bacterial microbiome and are still not well known. Thus, general conclusions and potential therapeutic implications regarding the microbiome will continue to be limited to an indeterminate degree by the myriad of dispositional and exposure-related influencing factors.

**Conclusions**

In this study we observed that: 1) There were no significant differences in the absolute bacterial load and β-diversity of the microbiome between the control group and OSA group, although patients with severe OSA showed increased α-diversity compared to the control group, while those with moderate OSA showed decreased α-diversity; 2) The evaluation of longitudinal changes in the nasal microbiota during CPAP treatment showed no significant difference in α- or β-diversity; 3) The most abundant taxa in all groups were Corynebacteriaceae, Carnobacteriaceae and Staphylococcaceae. In the linear discriminant analysis, Xanthobacteraceae were more abundant in the nasal microbiome of OSA patients, while Brucellaceae, Burkholderiales incertae sedis and Erysipelothrichaceae were more abundant in the nasal microbiome of the healthy control group; 4) In relation to CPAP treatment in patients with moderate and severe OSA, the number of different bacteria, in the linear discriminant analysis, decreased and the biodiversity seems to approach that of the control group. This alignment of the composition of the nasal microbiome in pa-
tients with moderate and severe OSA, as well as an alignment of its biodiversity with that of the healthy control group during CPAP treatment, could be both part of the therapeutic effect in CPAP therapy and a promoting factor of the adverse side effects of the therapy. Further studies are now needed to investigate whether the imbalance of the endonasal microbiome is related to CPAP compliance and whether therapeutic modification of the microbiome in the future with probiotics, microbiota transplantation, different mask surfaces or water reservoirs, would have possible clinical implications in terms of improving CPAP treatment adherence and tolerance.

Acknowledgments
The authors would like to thank Dr. Magdalene Ortmann for her statistical assistance. We gratefully appreciate the support of Holger Meixner and Astrid Taut with technical assistance. Microbiome analysis was supported by the Core-Unit MACE of the UKER. The present work was performed in fulfilment of the requirements for obtaining the degree of Dr. med. by Christian Lenk at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).

Funding
This study was funded in full by the Friedrich-Alexander-Universität Erlangen-Nürnberg.

Conflict of Interest
The authors declare no competing interests.

Ethics Approval
This study involving human participants was conducted in accordance with the amended Declaration of Helsinki and was approved by the Ethics Committee of the Friedrich-Alexander-Universität Erlangen-Nürnberg (Ref-No. 284_16 B).

Informed Consent
Informed consent was obtained from all individual participants included in the study.

Authors’ Contributions
Christian Lenk, Maximilian Traxdorf and Elena Messbacher contributed substantially to the concept and design of the study. Christian Lenk and Elena Messbacher performed data collection. Christian Lenk and Maximilian Traxdorf were responsible for interpretation, drafting, monitoring and validation of the article. All authors discussed the results, commented on the paper and gave their final approval of the version of the article to be published.

ORCID ID
Christian Lenk: 0000-0003-4013-599X

Conflict of Interest
The authors declare that they have no personal and financial relationships with other people or organizations that could influence this paper. The authors declare that they have no conflict of interest to declare.

Availability of Data and Materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

References
Nasal microbiome in OSA and CPAP-treatment


34) Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic bio-


